{'fraction_non_alphanumeric': 0.02243211334120425, 'fraction_numerical': 0.0070838252656434475, 'mean_word_length': 6.066666666666666, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Nosocomial Neonatal Meningitis with Acinetobacter Baumannii on Myelomeningocele: A Real Therapeutic Challenge

Imipenem-resistant Acinetobacter baumannii meningitis is a hospital-acquired infection, the treatment of which constitutes a real therapeutic challenge. In this article, together with a review of the literature, we report two cases of imipenem-resistant Acinetobacter baumannii neonatal meningitis following ruptured myelomeningocele, treated with intravenous colistin with favorable results. In recent years, Acinetobacter baumannii has become a more and more commonly described pathogen in hospital-acquired infections. However, the cases of meningitis are mainly postoperative and are still not quite frequently described in the literature. Colistin appears to be preferably administered intravenously at a dose of 100.000 IU/kg/day.